Corporate presentation and live webcast scheduled for Thursday, November 19, 2020 at 2:55 PM ET AUSTIN, Texas --(BUSINESS WIRE)--Nov. 12, 2020-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products

Signs Letter of Intent with Felix Biotechnology to license Thin Film Freezing technology for their bacteriophage products for lung inhalation Signs worldwide co-development agreement with Augmenta Bioworks for monoclonal antibody therapeutics Reports positive preclinical immunogenicity and efficacy

Felix Biotechnology would obtain worldwide license for Thin Film Freezing technology to develop a novel, bacteriophage-based biotherapeutic Proposed terms provide for upfront payments, clinical development milestone and commercial milestone payments to TFF Pharmaceuticals of up to $281 million , as